HFrEF Presentation - Auto Slideshow

FIRST LINE GDMT

Beta Blocker

Aldosterone Inhibitor

ACEI/ARB/ARNI

SGLT-2 Inhibitor

Isordil/Hydralazine

Vericiguat

Ivabradine

Digoxin

SECOND LINE GDMT

DID YOU KNOW?

Optimal GDMT can reduce mortality by over 0, while significantly enhancing the quality of life for patients with HFrEF.
Lead the Change with Breakthrough Therapies
Sacubitril/Valsartan: Redefining neurohormonal modulation in heart failure.
Dapagliflozin: Transforming cardiorenal care.
Together, these therapies are at the forefront of a revolution in HFrEF treatment, empowering physicians to deliver life-changing results.

Elevate Heart Failure Treatment: Embrace the Power of GDMT with

To reduce the risk of CV death & Hospitalization in Chronic Heart Failure

℞

SACUVAN

Sacubitril Valsartan
26, 49/51 & 97/103 mg Tablets

&

In Congestive Heart Failure

℞

Glyda

Dapagliflozin 5 mg/10 mg Tablets

Heart Failure Fighters: GDMT's Fantastic Four

Heart Failure with Reduced Ejection Fraction (HFrEF)

Simultaneous or rapid sequence initiation of GDMT

All patients

Guideline-Directed Medical Therapy

ARNi

ACEI ARB

↓

RAAS
inhibition

BB

↓

Sympathetic
activation

MRA

↓

Aldosterone
inhibition

SGLT2i

↓

Osmotic
diuresis & natriuresis

Benefits

↓ Preload
↓ Afterload
↓ Myocardial O₂ demand
↑ Coronary perfusion
↑ Reverse cardiac remodeling

Early GDMT saves lives, prevents readmissions, and enhances living

Elevate Heart Failure Treatment: Embrace the Power of GDMT with

To reduce the risk of CV death & Hospitalization in Chronic Heart Failure

℞

SACUVAN

Sacubitril Valsartan
26, 49/51 & 97/103 mg Tablets

&

In Congestive Heart Failure

℞

Glyda

Dapagliflozin 5 mg/10 mg Tablets

CONVENTIONAL SEQUENCING

Step 1

ACE inhibitor or angiotensin receptor blocker

Step 2

Beta-blocker

Step 3

Mineralocorticoid receptor antagonist

Step 4

Angiotensin receptor neprilysin inhibitor

Step 5

SGLT2 inhibitor

Up titration to target doses at each step Typically requires 6 months or more

RAPID SEQUENCING

Step 1

ARNI + Beta-blocker + MRA

Step 2

Add SGLT2 inhibitor

Step 3

Up titration to target doses

All 3 steps achieved within 4 weeks Up titration to target doses thereafter

SGLT2: Sodium-glucose cotransporter-2. Ref.: Packer M, et al. Eur J Heart Fail. 2021;23:882-894.

Elevate Heart Failure Treatment: Embrace the Power of GDMT with

To reduce the risk of CV death & Hospitalization in Chronic Heart Failure

℞

SACUVAN

Sacubitril Valsartan
26, 49/51 & 97/103 mg Tablets

&

In Congestive Heart Failure

℞

Glyda

Dapagliflozin 5 mg/10 mg Tablets

PARADIGM-HF Trial¹

20% reduction in cardiovascular death or HF hospitalization compared to enalapril in patients with HFrEF already receiving MRAs and Bbs.

Empower Your HF Patients with Evidence-Based Care.

DAPA-HF Trial²

26% reduction in the composite risk of cardiovascular death or worsening HF, even in patients already receiving MRAs and Bbs.

Dapagliflozin and Sacubitril/Valsartan - Redefining the Standard in Heart Failure Management

Ref 1: n engl j med 371;11 nejm.org september 11, 2014

2: n engl j med 381,21 nejm.org November 21, 2019

Elevate Heart Failure Treatment: Embrace the Power of GDMT with

To reduce the risk of CV death & Hospitalization in Chronic Heart Failure

℞

SACUVAN

Sacubitril Valsartan
26, 49/51 & 97/103 mg Tablets

&

In Congestive Heart Failure

℞

Glyda

Dapagliflozin 5 mg/10 mg Tablets

Improves cardiac function in patients with HFrEF
Greater reduction in LAD and NT-proBNP levels compared to Sacubitril/Valsartan monotherapy
Offers more potent cardiovascular benefits
Improved cardiac function, In patients with HFrEF
ARNI & Dapagliflozin showed an independent reduction in CV death and HF
Exerted better effects than ACEI or ARB
Reduces morbidity and mortality in patients with HFrEF

BETTER GLYCAEMIC CONTROL

0.89%

A1c

Reduction¹

24 hr

Glycaemic

control²

Weight Reduction⁴

-3.22

kg

CV Benefits

27%

RRR*

of hHF³**

Reduction in BP⁵

-4.3

mmHg

Elevate Heart Failure Treatment: Embrace the Power of GDMT with

To reduce the risk of CV death & Hospitalization in Chronic Heart Failure

℞

SACUVAN

Sacubitril Valsartan
26, 49/51 & 97/103 mg Tablets

&

In Congestive Heart Failure

℞

Glyda

Dapagliflozin 5 mg/10 mg Tablets

INDICATION

For adults with chronic heart failure-reduces CV death and hospitalization, with greatest benefit in low LVEF

DOSAGE AND ADMINISTRATION*

Indication	Titration Step Dose (Twice daily)
	Starting	Second	Final
Adult heart Failure	49/51 mg	97/103 mg
Pediatric Heart Failure Patients ≤ 40 kg	1.6 mg/kg	2.3 mg/kg	3.1 mg/kg
Pediatric Heart Failure Patients 40 kg to 50 kg	24/26 mg	49 / 51 mg	75 / 78 mg
Pediatric Heart Failure Patients ≥ 50 kg	49/51 mg	72 / 78 mg	97 / 103 mg

PACKSHOT

INDICATION

To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors

DOSAGE

Type 2 Diabetes Mellitus:

To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established
CV disease or multiple CV risk factors: 10 mg once daily.
Heart Failure: Recommended dose is 10 mg once daily.

(Not recommended for glycemic control when the eGFR is less than 45 mL/min/1.73 m², Assess renal function before initiating and then as clinically indicated.)

The Race doesn't end with Beta-Blockers -

Even on GDMT, the Heart often refuses to slow down#

It's time to intervene

where others can't -Heart Rate*

*Since Lower heart rate (HR) is associated with a better prognosis in heart failure (HF).

In HFrEF (LVEF ≤35%) patients with sinus rhythm & HR ≥70 bpm,
to reduce hospitalizations when beta-blockers are optimized or not tolerated

GDMT: Guideline-directed Medical Therapy

In HFrEF (LVEF ≤35%) patients with sinus rhythm & HR ≥70 bpm,
to reduce hospitalizations when beta-blockers are optimized or not tolerated

SHIFT Trial: Ivabradine Demonstrates Efficacy & Safety in High-Risk HFrEF Patients irrespective of SBP, LVEF, or NYHA Class¹

18%

Relative risk reduction in the primary endpoint.

26%

Significant reduction in heart failure hospitalizations.

Click to read article

Settings

HFrEF: A CHALLENGE WE CAN OVERCOME

First line GDMT having class I recommendations in the 2022 AHA/ACC/HFSA guidelines for HFrEF

FIRST LINE GDMT

SECOND LINE GDMT

DID YOU KNOW?

Rapid Evidence-Based Sequencing of Foundational Drugs for HFrEF

Benefits

Rapid Evidence-Based Sequencing of Foundational Drugs for HFrEF

CONVENTIONAL SEQUENCING

RAPID SEQUENCING

Two Proven Paths for Stronger Hearts and Lasting Protection

Two Proven Paths for Stronger Hearts and Lasting Protection

Two Proven Paths for Stronger Hearts and Lasting Protection